GA
GALT.US Galectin Therapeutics Inc
- Market cap
- USD 308M
- P/E
- -
- P/B
- 207.70x
- ROE
- -
- Dividend yield
- 0.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GALT.US undervalued?
Graham numberThe Graham number of Galectin Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Galectin Therapeutics Inc fundamental analysis
No fundamental analysis for Galectin Therapeutics Inc yet.
Galectin Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc…
Full company profileGalectin Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Galectin Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.00K | -1.00K | -1.00K | -35.0K | -36.0K | -41.0K | -32.0K | -33.0K | -37.0K | - | - |
| Operating Income | -21.5M | -16.2M | -13.6M | -13.4M | -23.4M | -30.2M | -38.4M | -38.1M | -42.4M | -20.1M | -16.1M |
| EBITDA | -21.5M | -16.2M | -13.6M | -13.2M | -23.3M | -30.0M | -37.7M | -38.2M | -41.5M | -23.5M | -7.74M |
| Net Income | -21.4M | -16.2M | -13.9M | -13.3M | -23.5M | -30.5M | -38.8M | -41.1M | -47.0M | -30.8M | -28.3M |
| EPS | -0.73 | -0.46 | -0.35 | -0.25 | -0.41 | -0.52 | -0.65 | -0.68 | -0.76 | -0.48 | -0.43 |
| Balance Sheet | |||||||||||
| Total Assets | 15.8M | 4.16M | 9.01M | 48.5M | 29.6M | 41.8M | 21.3M | 28.2M | 17.5M | 19.5M | 14.8M |
| Total Liabilities | 3.78M | 2.97M | 2.11M | 2.87M | 5.41M | 39.2M | 53.5M | 88.4M | 121M | 146M | 152M |
| Shareholders' Equity | 12.0M | 1.19M | 6.90M | 45.6M | 24.2M | 2.62M | -32.2M | -60.2M | -103M | -126M | -137M |
| Cash & Short-term Investments | 15.4M | 3.05M | 8.25M | 47.5M | 27.1M | 39.6M | 18.6M | 25.7M | 15.1M | 17.7M | 13.3M |
| Total Debt | - | - | - | 39.0K | 44.0K | 29.1M | 39.9M | 71.8M | 106M | 134M | 138M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.4M | -15.9M | -10.2M | -10.8M | -20.6M | -24.3M | -31.1M | -33.0M | -41.8M | -23.9M | -12.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -16.4M | -15.9M | -10.2M | -10.8M | -20.6M | -24.3M | -31.1M | -33.0M | -41.8M | -23.9M | -12.6M |
| Ratios | |||||||||||
| ROE | -178.4% | -1,360.9% | -201.5% | -29.2% | -97.0% | -1,166.9% | - | - | - | - | - |
| ROA | -135.7% | -390.2% | -154.3% | -27.4% | -79.3% | -73.0% | -182.2% | -145.6% | -268.9% | -157.9% | -191.0% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 11.11x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Galectin Therapeutics Inc dividends
- Dividend yield
- 0.04%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 138K | 0.00 | - |
| 2024 | USD 91.0K | 0.00 | - |
| 2023 | USD 120K | 0.00 | - |
| 2022 | USD 97.0K | 0.00 | - |
| 2021 | USD 171K | 0.00 | - |
| 2020 | USD 137K | 0.00 | - |
| 2019 | USD 394K | 0.01 | - |
| 2018 | USD 915K | 0.02 | - |
| 2017 | USD 1.23M | 0.03 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:6 on Mar 23, 2012.
Who owns Galectin Therapeutics Inc
- Insiders 52.80%
- Institutions 16.05%
- Public & others 31.16%
- Shares outstanding 101M
- Free float 47.9M
Top funds holding GALT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.52M | 1.51% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.16M | 1.15% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 528K | 0.52% | +1.50% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 313K | 0.31% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 280K | 0.28% | +1.59% | Sep 2026 |
| Fidelity Extended Market Index | 225K | 0.22% | -14.61% | Sep 2026 |
| iShares Russell 2000 Value ETF | 156K | 0.15% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 144K | 0.14% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 116K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 96.6K | 0.10% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 89.6K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 82.2K | 0.08% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 63.7K | 0.06% | 0.00% | Aug 2026 |
| Schwab Total Stock Market Index | 55.4K | 0.05% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 48.0K | 0.05% | +142.30% | Jun 2026 |
| EQ/2000 Managed Volatility IB | 47.7K | 0.05% | 0.00% | Sep 2026 |
| Horizon Kinetics Medical ETF | 42.5K | 0.04% | 0.00% | Oct 2026 |
Top institutions holding GALT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 2.99M | 2.96% | +273.90% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.17M | 2.15% | +10.25% | Jun 2026 |
| Geode Capital Management, LLC | 1.31M | 1.30% | +113.52% | Jun 2026 |
| Advisor Group Holdings, Inc. | 1.20M | 1.19% | +7.22% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 831K | 0.82% | -31.88% | Jun 2026 |
| Sontag Advisory LLC | 722K | 0.72% | 0.00% | Jun 2026 |
| State Street Corp | 568K | 0.56% | +119.70% | Jun 2026 |
| Commonwealth Equity Services, LLC | 407K | 0.40% | +10.90% | Jun 2026 |
| Northern Trust Corp | 387K | 0.38% | +196.32% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 366K | 0.36% | +20.46% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 328K | 0.33% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 318K | 0.32% | -31.86% | Jun 2026 |
| LPL Financial Corp | 285K | 0.28% | +6.80% | Jun 2026 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 261K | 0.26% | +103.11% | Jun 2026 |
| Sovran Advisors, LLC | 258K | 0.26% | +0.06% | Jun 2026 |
| Geneos Wealth Management Inc | 240K | 0.24% | -0.21% | Jun 2026 |
| UBS Group AG | 219K | 0.22% | +22.02% | Jun 2026 |
| RETIREMENT GUYS FORMULA LLC | 211K | 0.21% | +12.83% | Jun 2026 |
| Citadel Advisors Llc | 199K | 0.20% | -31.57% | Jun 2026 |
| Susquehanna International Group, LLP | 177K | 0.18% | -68.11% | Jun 2026 |
Galectin Therapeutics Inc company profile
- Company name
- Galectin Therapeutics Inc
- Ticker
- GALT.US
- Exchange
- USA Stocks
- Listed since
- Sep 9, 2002
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071
- Phone
- 678 620 3186
- Website
- galectintherapeutics.com
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc management
6- Mr. Joel Lewis CPAPresident & CEO · born 1970
- Mr. Jack W. Callicutt CPACFO, Treasurer & Corporate Secretary · born 1967
- Dr. Khurram Jamil M.D.Chief Medical Officer · born 1976
- Mr. Robert Tritt J.D.General Counsel
- Mr. Jim Wilkins Ph.D.Head of CMC & Pharmaceutical Development
- Ms. Beth KnowlesExecutive Assistant & Officer Manager